Related by context. All words. (Click for frequent words.) 67 molecular remissions 66 complete remissions 66 OHR/AVR# 66 heavily pretreated 65 tumor regression 65 tumor regressions 65 relapsed ovarian cancer 65 complete cytogenetic response 64 DACH platinum 64 pegylated liposomal doxorubicin 64 chemotherapy docetaxel 64 antiangiogenic therapy 64 pegfilgrastim 64 lumiliximab 64 CHOP chemotherapy 64 bendamustine 64 amrubicin 64 OncoVEX GM CSF 64 systemic toxicity 64 Gleevec resistant 64 EndoTAG TM -1 64 HuMax CD4 64 doxorubicin docetaxel 64 anti leukemic 64 cisplatin chemotherapy 64 chlorambucil 63 cardiotoxic 63 CIMZIA ™ 63 Bezielle 63 Telintra 63 NNRTI resistance 63 teriflunomide 63 pCR 63 cytoreduction 63 ProSavin 63 surgical debulking 63 heavily pretreated patients 63 oblimersen 63 imatinib therapy 63 XmAb# 63 chemoradiotherapy 63 taxane refractory 63 antiangiogenic agent 62 Symadex 62 alkylating agent 62 Velcade bortezomib 62 adjuvant cisplatin 62 TNF alpha antagonist 62 CCyR 62 PSMA ADC 62 estramustine 62 Natalizumab 62 interferon therapy 62 pomalidomide 62 DXL# 62 taxane chemotherapy 62 tafamidis 62 chemoresistant 62 favorable tolerability 62 mTOR inhibition 62 ISF# 62 cytotoxic therapy 62 sustained virological response 62 GAP #B# 62 inecalcitol 62 decitabine 62 ponatinib 62 TREANDA 62 dose cohort 62 riociguat 62 neurologic progression 62 corticosteroid dexamethasone 62 nephrotoxicity 62 Xanafide 62 virologic suppression 62 omega interferon 62 OncoVEX 61 cilengitide 61 anti EGFR antibody 61 mRCC 61 antiangiogenic agents 61 triphendiol 61 paclitaxel Taxol ® 61 intravenous cyclophosphamide 61 sipuleucel T 61 recurrent glioblastoma multiforme 61 goserelin 61 Azedra 61 IMA# 61 HuMax CD# 61 KRAS wild 61 partial remissions 61 hematologic toxicity 61 recurrent glioblastoma 61 androgen deprivation 61 INCB# [001] 61 plasminogen activators 61 relapsed MM 61 Factor Xa inhibitors 61 HuLuc# 61 GnRH antagonist 61 5FU 61 R0 resection 61 lapatinib Tykerb 61 Bortezomib 61 favorable pharmacokinetic profile 61 forodesine 61 Cimzia TM 61 axitinib 61 interferon beta 61 prolongs survival 61 mTOR inhibitors 61 Aptivus ® 61 mCRC patients 61 TKI therapy 61 postoperative chemotherapy 61 irinotecan chemotherapy 61 dacarbazine 61 Combination therapy 61 tamoxifen therapy 61 metastatic CRC 61 ACZ# 61 chemopreventive agent 61 Doxil ® 61 ELACYT 61 antitumor effect 61 Trastuzumab 61 PegIFN RBV 61 ZOLINZA 61 BRAF inhibitors 61 liposomal formulation 61 obatoclax 61 Seliciclib 61 tumor necrosis 61 APTIVUS r 61 Erlotinib 61 AMN# [001] 61 virological suppression 61 monoclonal antibody therapies 61 recurrent metastatic 61 TTF Therapy 61 otelixizumab 61 lenalidomide Revlimid R 60 imetelstat 60 TG# [003] 60 CytoFabTM 60 Traficet EN 60 UPLYSO 60 tolevamer 60 Platinol 60 metastatic RCC 60 evaluable subjects 60 locoregional recurrence 60 bortezomib Velcade 60 CIMZIA TM 60 ANAVEX #-# [001] 60 IFN α 60 CRp 60 Pemetrexed 60 FluCide 60 VEGF inhibitors 60 relapsed AML 60 Virulizin ® 60 pertuzumab 60 orally bioavailable 60 octreotide LAR 60 LHRH agonists 60 antiandrogen 60 anagrelide 60 KRAS mutations occur 60 chemo radiotherapy 60 VIDAZA 60 intravenous dosing 60 MS relapses 60 DCVax R Brain 60 MGd 60 remission CR 60 myelosuppression 60 pharmacokinetic interactions 60 anti angiogenic agents 60 lung metastasis 60 nephrotoxic 60 MAGE A3 ASCI 60 tanespimycin 60 relapsed SCLC 60 relapsed ALL 60 p# activation 60 concurrent chemoradiation 60 dasatinib Sprycel 60 PROCHYMAL 60 metaglidasen 60 Doxorubicin 60 vidofludimus 60 trastuzumab Herceptin ® 60 Amrubicin 60 Amplimexon 60 melphalan prednisone 60 TroVax ® 60 CMV disease 60 octreotide 60 HBeAg seroconversion 60 HCV protease inhibitors 60 CTAP# Capsules 60 OPAXIO 60 mycophenolate mofetil 60 neoadjuvant chemotherapy 60 Cytolin R 60 mutated K ras 60 VELCADE melphalan 60 neurotrophic 60 TYSABRI natalizumab 60 dacetuzumab 60 opioid analgesia 60 Pertuzumab 60 Arranon 60 EGFR inhibitors 60 colorectal cancer liver metastases 60 Tavocept 60 rindopepimut 60 combinability 60 angiographic restenosis 60 complete cytogenetic 60 lupus nephritis 60 sitaxsentan 60 gefitinib 60 HbF 60 Interferon beta 60 nucleotide analog 60 PSA nadir 60 interferon beta therapy 60 Interferon alpha 60 intravenous bisphosphonates 60 DFMO 60 lenalidomide dexamethasone 60 talabostat 60 metastatic uveal melanoma 60 cidofovir 60 transgene expression 60 chemotherapeutic drug 60 CIMZIA TM certolizumab pegol 60 gemcitabine Gemzar 60 rtPA 60 gemifloxacin 60 virological failure 60 imatinib Gleevec 60 immune reconstitution 60 systemic ALCL 60 vandetanib 60 viral suppression 60 Technosphere Insulin 60 rituximab Rituxan 60 Flu Cy 59 cytostatic 59 CBLC# 59 malignant ascites 59 nadolol 59 standard chemotherapy regimen 59 PROMACTA 59 enoximone 59 immunomodulatory therapy 59 cardiac repolarization 59 temsirolimus 59 pamidronate 59 TOCOSOL Paclitaxel 59 TELINTRA 59 EFAPROXYN 59 pediatric acute lymphoblastic 59 potentially hepatotoxic 59 mutated KRAS 59 Gliadel Wafer 59 candidemia 59 paclitaxel eluting stents 59 lomitapide 59 MabCampath 59 antitumor activity 59 highly immunogenic 59 Gefitinib 59 schizophrenia CIAS 59 refractory metastatic colorectal cancer 59 caspofungin 59 entinostat 59 curative therapy 59 Cytolin ® 59 alvespimycin 59 mutant KRAS 59 IL 1ß 59 metastatic lesions 59 G#DT 59 abiraterone 59 LHRH 59 angiographic outcomes 59 remission induction 59 steroid dexamethasone 59 gemcitabine cisplatin 59 achieve sustained virologic 59 interferon ribavirin 59 Proxinium TM 59 standard chemotherapy regimens 59 proteasome inhibitor 59 Genz # 59 elacytarabine 59 overlapping toxicities 59 neoadjuvant therapy 59 Dasatinib 59 elotuzumab 59 Panzem R NCD 59 cabazitaxel 59 cisplatin vinorelbine 59 interferon IFN 59 thrombocytopenic patients 59 thalidomide dexamethasone 59 SERMs 59 immune modulator 59 statistically significant efficacy 59 IRX 2 59 docetaxel chemotherapy 59 calcineurin inhibitor 59 erlotinib Tarceva 59 ATL/TV# 59 superficial bladder cancer 59 colorectal liver metastases 59 indibulin 59 EGFRIs 59 canakinumab 59 uric acid lowering 59 alefacept 59 SCCHN 59 ganetespib 59 KRAS mutant tumors 59 Glypromate 59 circulating EPCs 59 SCIg 59 TAXOTERE ® 59 farletuzumab 59 tumor resection 59 micafungin 59 CR nPR 59 dasatinib 59 Arikace 59 anticancer treatments 59 small molecule tyrosine 59 AP# [003] 59 AGHD 59 Cloretazine R VNP#M 59 adriamycin 59 PKCi 59 MYLOTARG 59 Viramidine 59 prednisone prednisolone 59 haematologic 59 anthracycline containing 59 MyVax 59 pegylated interferon alfa 59 AEG# 59 thalidomide Thalomid 59 locoregional disease 59 adjuvant tamoxifen 59 cannabinor 59 Cetuximab 59 Cytoxan 59 MyVax ® 59 TNF alpha inhibitor 59 clodronate 59 PRT# 59 oxaliplatin Eloxatin 59 etoposide 59 Fludara 59 cranial irradiation 59 VEGF inhibition 59 fluoropyrimidine 59 antimetabolite 59 recombinant enzyme 59 convenient dosing regimens 59 virological response 59 Fludarabine 59 evaluating tivozanib 59 cytotoxic chemotherapy 59 peak plasma concentrations 59 malignant pleural mesothelioma 59 Campath alemtuzumab 59 gefitinib Iressa 59 GnRH agonist 59 DCVax ® 59 5-fluorouracil/leucovorin 59 Epanova 59 carboplatin paclitaxel 59 XYOTAX 59 humanized antibody 59 ONTAK 59 biologic therapy 59 IV bisphosphonates 59 anthracycline taxane 59 ONCONASE 59 CA4P 59 eosinophilic asthma 59 Fibrillex TM 59 Dextofisopam 59 ispinesib administered 59 relapsed MCL 59 Aloxi injection 59 indolent NHL 59 EXJADE 59 LEP ETU 59 SVR# 59 trabedersen 59 Treg cell 59 immune modulating 59 milatuzumab 59 azacitidine 58 GVAX 58 VA# [002] 58 Pegylated Interferon 58 CYT# potent vascular disrupting 58 vinorelbine 58 platinum refractory 58 cardiac toxicity 58 HspE7 58 hormone refractory 58 cytotoxic agents 58 BRAF V# mutation 58 taxane 58 chemotherapeutic regimens 58 surrogate endpoint 58 metastatic renal cell 58 HGS ETR1 58 virologic failure 58 anti angiogenic therapy 58 xenograft models 58 Vidaza azacitidine 58 IFN beta 58 Onconase 58 adalimumab Humira 58 alteplase 58 allogeneic HSCT 58 Altastaph 58 trans retinoic acid ATRA 58 operable breast cancer 58 androgen ablation 58 oncologic outcomes 58 immunosuppressive regimens 58 idarubicin 58 dose dexamethasone 58 BrachySil 58 locoregional 58 CYP #A# 58 mg kg dose 58 metastatic malignant 58 tamoxifen Nolvadex ® 58 platelet inhibitor 58 DAC HYP 58 Aflibercept 58 mitoxantrone 58 antiangiogenic 58 interferon alpha 2b 58 KRAS status 58 RLY# 58 HER2 overexpression 58 liver metastases 58 Xelox 58 metastatic kidney 58 demonstrated antitumor activity 58 Elitek 58 EGFR TKI 58 virologic response 58 Revimmune 58 antiandrogens 58 dosing frequency 58 hematological toxicity 58 DAPT 58 preoperative chemotherapy 58 refractory AML 58 PPAR gamma agonists 58 BEXXAR 58 carfilzomib 58 CCX# 58 metastatic neuroendocrine tumors 58 bleomycin 58 CR CRu 58 arsenic trioxide ATO 58 CDK inhibitor 58 nab paclitaxel 58 relapsed CLL 58 DIFICID 58 oral ridaforolimus 58 docetaxel Taxotere 58 rituximab monotherapy 58 antiviral potency 58 protease inhibitor PI 58 chronic GVHD 58 curative resection 58 erythropoietic 58 MyVax R 58 chemotherapeutic 58 dose escalation phase 58 vivo potency 58 renal toxicity 58 BNC# 58 Tarvacin 58 ENMD # 58 achieved sustained virological 58 ORENCIA R 58 VDAs 58 Zevalin consolidation 58 thrombotic complications 58 Cloretazine 58 B CLL 58 APTIVUS R 58 dosing cohort 58 Fibrillex 58 oral FTY# 58 MYDICAR 58 lanthanum carbonate 58 ixabepilone 58 radiochemotherapy 58 MCyR 58 endostatin 58 platelet reactivity 58 telomerase inhibition 58 GvHD 58 ularitide 58 Hepatocellular Carcinoma HCC 58 ATL# [001] 58 Gleevec imatinib 58 ribavirin therapy 58 refractory acute myeloid 58 FTY# 58 antitumor 58 Endeavor DES 58 Febrile neutropenia 58 antithrombotic therapy 58 phase IIb trial 58 oral rivaroxaban 58 clinically meaningful efficacy 58 Zemplar Capsules 58 Hedgehog inhibitor 58 TELCYTA 58 Octreolin 58 effector function 58 masitinib 58 MetMAb 58 tumor shrinkage 58 Tarceva TM 58 Lung transplantation 58 DCVax ® Brain 58 oral clodronate 58 FOLFIRINOX 58 RoACTEMRA 58 indolent lymphomas 58 atacicept 58 Intravenous CP 58 cytogenetic responses 58 receptor blocker 58 Sym# 58 antitumor effects 58 aprepitant 58 CoFactor 58 deferiprone 58 samalizumab 58 hepatic fibrosis 58 AChE inhibitors 58 fondaparinux 58 fulvestrant 58 ibandronate 58 pancreatic adenocarcinoma 58 cranial radiation 58 virologic responses 58 NNRTIs 58 AMPK activators 58 elagolix 58 trabectedin 58 tipifarnib 58 sorafenib Nexavar 58 neointimal hyperplasia 58 galiximab 58 SERCA2a 58 Vandetanib 58 moderately emetogenic 58 adult chronic ITP 58 viral kinetics 58 Dacogen decitabine 58 personalized immunotherapy 58 Taxotere chemotherapy 58 sustained virologic response 58 docetaxel Taxotere ® 58 virologic breakthrough 58 Azixa 58 pitavastatin 58 talactoferrin 58 carboplatin chemotherapy 58 Kinoid 58 Mylotarg 58 myeloablative 58 dose cyclophosphamide 58 leukemia AML 58 alemtuzumab treated 58 undetectable viral loads 58 anti angiogenic drugs 58 plasma uric acid 58 intradermal injection 58 sunitinib 58 Neuvenge 58 liver metastasis 58 gemcitabine carboplatin 58 CMV infection 58 paclitaxel Taxol 58 lipid lowering therapies 58 FOSRENOL ® 58 pegylated interferons 58 amphotericin B 58 bone marrow suppression 58 Alemtuzumab 58 dexanabinol 58 tezampanel 58 chemotherapeutic regimen 58 everolimus eluting stents 58 initiate Phase 1b 58 panobinostat 58 invasive candidiasis 58 nilotinib 58 bezafibrate 58 Thal Dex 58 debulking surgery 58 docetaxel prednisone 58 K ras mutations 58 Panitumumab 58 HuMax EGFr 58 cytogenetic response 58 hA# 58 VAPRISOL 58 FOLFOX4 58 letrozole Femara 58 cetuximab Erbitux ® 58 hypercalcemia 58 anti TNF 58 haematological toxicity 58 nucleoside analogues 57 Allovectin 7 R 57 ovarian carcinoma 57 AAV vectors 57 cisplatin resistant 57 Benlysta belimumab 57 HGS# 57 LHRH agonist 57 antiangiogenic activity 57 Dendreon Provenge 57 HBV vaccine 57 symptomatic paroxysmal AF 57 PAOD 57 TYKERB 57 tipranavir 57 cediranib 57 anticancer therapies 57 serum urate levels 57 pegylated interferon alpha 57 null responder 57 antitumor responses 57 oral Hycamtin 57 antibody mediated 57 HGS ETR2 57 skeletal metastases 57 RSD# 57 trastuzumab DM1 57 gemcitabine Gemzar ® 57 pyridostigmine 57 adrenal suppression 57 PEGPH# 57 GRN#L 57 B7 H3 57 CLL SLL 57 Tocosol Paclitaxel 57 chemosensitivity 57 advanced NSCLC 57 potent cytotoxic 57 HSP# inhibitor 57 Gemzar ® 57 rhIL 7 57 resectable 57 corrected QT interval 57 IRESSA 57 EBV infection 57 MEK inhibitors 57 CsA 57 ImmunoVEX HSV2 57 Smac mimetic 57 TRISENOX 57 TBC# 57 rFIXFc 57 low dose cytarabine 57 dirucotide 57 hemorrhagic complications 57 radiation sensitizer 57 cytotoxic 57 leukemic cell 57 metastatic malignant melanoma 57 CaPre TM 57 variceal hemorrhage 57 phase IIb clinical 57 Octreotide 57 Sutent sunitinib 57 acute GvHD 57 Provecta 57 cardiotoxicity 57 cetuximab Erbitux 57 tipranavir r 57 azacytidine 57 adjuvant radiation 57 PRESEPT study 57 EOquin TM 57 Toxicities 57 taxane therapy 57 elvucitabine 57 allogeneic stem cell 57 zoledronate 57 MOZOBIL 57 intracranial hemorrhage ICH 57 AGILECT R 57 Allovectin 7 57 regorafenib 57 achieved ACR# 57 TAXOTERE R 57 trastuzumab 57 Nicole Onetto MD 57 BCG refractory 57 oral prodrug 57 Virulizin R 57 CIPN 57 adjuvant radiotherapy 57 eltrombopag 57 INT# [002] 57 epirubicin 57 PhG alpha 1 57 Ceplene/IL-2 57 Gleevec imatinib mesylate 57 #ME# 57 Mipomersen 57 YONDELIS 57 ancrod 57 mg/m2 cohort 57 S/GSK# 57 MAXY G# 57 Aplidin 57 parkinsonian symptoms 57 tocilizumab 57 SNT MC# 57 beta interferon 57 #mg dose [001] 57 fibrotic disease 57 Allovectin 7 ® 57 PEGylated interferon beta 1a 57 chronic lymphocytic leukemia CLL 57 gemcitabine chemotherapy 57 systemically administered 57 Troxatyl 57 immunosuppressive regimen 57 anticancer therapy 57 ciclosporin 57 Raptiva ® 57 paclitaxel poliglumex 57 abatacept 57 gastrointestinal stromal tumors GIST 57 TACE 57 Neulasta ® 57 NEUGENE 57 ProLindac 57 hour bronchodilation 57 BrachySil TM 57 Onrigin 57 novel VDA molecule 57 bronchodilatory 57 GIST tumors 57 sargramostim 57 FOLFOX6 57 Sandostatin LAR 57 selective agonist 57 angiogenesis inhibitor 57 Hydroxyurea 57 PLX# 57 malignant transformation 57 Avastin Tarceva 57 anti angiogenic therapies 57 Reverset 57 generation purine nucleoside 57 non metastatic osteosarcoma 57 CVP chemotherapy 57 omacetaxine mepesuccinate 57 tyrosine kinase inhibitors 57 chemotherapeutic agent 57 Ophena TM 57 Ventavis ® 57 rFVIIa 57 custirsen 57 plus dexamethasone 57 imatinib mesylate Gleevec 57 romiplostim 57 5-FU/LV 57 chronic idiopathic thrombocytopenic purpura 57 Platinol ® cisplatin 57 EGFR tyrosine kinase inhibitors 57 tumor lysis syndrome 57 log# reduction 57 chemotherapy regimens 57 stavudine d4T 57 independent prognostic marker 57 darapladib 57 tumor histology 57 glioblastoma tumors 57 Etoposide 57 Abiraterone 57 NEVO ™ 57 activating EGFR mutations 57 recurrent genital herpes 57 Raptiva r 57 myelosuppressive chemotherapy 57 BZL# 57 β blockers 57 IMC A# 57 imatinib 57 inhibited tumor 57 orBec 57 Leukine 57 DOXIL 57 GHRH 57 convenient dosing regimen 57 medically inoperable 57 CLL cells 57 Novantrone 57 Cotara 57 Rituxan MabThera 57 anastrozole 57 TRIOLEX 57 PXD# 57 interferon alfa 2b 57 MabThera Rituxan 57 rFVIII 57 HRPC 57 investigational monoclonal antibody 57 darunavir r 57 receiving highly emetogenic 57 castrate resistant 57 tesmilifene 57 anticancer agent 57 molecularly targeted 57 Sanofi Aventis Taxotere 57 alemtuzumab Campath 57 SLx 57 rhIGF-I/rhIGFBP-3 57 Halaven 57 tremelimumab 57 IGF 1R inhibitor 57 squamous cell lung cancer 57 paclitaxel Taxol R 57 seliciclib 57 intraperitoneal therapy 57 hypofractionated radiation 57 dopamine partial agonist 57 bucindolol 57 pyrazinamide 57 CD# antibody [001] 57 hepatic toxicity 57 subcutaneous infusion 57 #beta estradiol 57 ceftazidime 57 PARP inhibitor 57 paclitaxel chemotherapy 57 fenretinide 57 myocardial reperfusion 57 serum urate 57 metastatic renal cell carcinoma 57 GBM tumors 57 vorinostat 57 trastuzumab Herceptin 57 pharmacologic intervention 57 HIV HCV coinfected 57 nucleoside analogs 57 BrachySil ™ 57 intensive lipid lowering 57 Tyrima 57 Alequel 57 BRAF inhibitor 57 JAK inhibitors 57 TriRima 57 bevacizumab Avastin 57 Roche Herceptin 57 Egrifta 57 relapsing remitting multiple sclerosis 57 posaconazole 57 beta interferons 57 Thalomid ® 57 alpha interferons 57 calcineurin inhibitors 57 Phase #/#a trial 57 tolterodine 57 velafermin 57 alicaforsen enema 57 TTR gene 57 antiangiogenic drugs 57 antithrombotic 57 glatiramer 57 leukemia ALL 57 undetectable HBV DNA 57 ARIKACE ™ 57 crizotinib PF # 57 CINTREDEKIN BESUDOTOX 57 transarterial chemoembolization 57 relapsed refractory 57 Lixivaptan 57 induce remission 57 antiarrhythmic drugs 57 MET inhibitor 57 Solazed 57 paliperidone ER 57 paclitaxel cisplatin 57 CLORETAZINE TM VNP#M 56 flavopiridol 56 ara C 56 amifostine 56 cytotoxic effects 56 ErbB2 positive 56 pharmacodynamic PD 56 orally dosed 56 Treanda 56 corticosteroid therapy 56 enzastaurin 56 HER2 positive cancers 56 Imprime PGG 56 RhuDex ® 56 Torisel 56 bronchodilation 56 MET amplification 56 nalbuphine ER 56 TNF inhibitor therapy 56 Pyridorin 56 isoproterenol 56 Vidofludimus 56 Phase 2a trial 56 receptor inhibitor 56 NEUMUNE 56 imatinib resistance 56 alkylating agents 56 hepatic encephalopathy HE 56 BAY #-# 56 bortezomib 56 immunomodulation 56 antiresorptive 56 selective modulator 56 Navelbine ® 56 daunorubicin 56 immune suppressive 56 Voreloxin 56 iniparib 56 relapsing multiple sclerosis 56 Retreatment 56 aromatase inhibitor therapy 56 fluvastatin 56 Roche Xeloda 56 nucleoside naive patients 56 lymphopenia 56 adefovir 56 methotrexate monotherapy 56 daclizumab 56 Twinrix 56 zalutumumab 56 refractory prostate cancer 56 therapeutic regimens 56 anthracycline therapy 56 olaparib 56 ritonavir boosted protease inhibitor 56 recurrent GBM 56 dexrazoxane 56 ruxolitinib 56 ARIMIDEX 56 liposomal doxorubicin 56 Irinotecan 56 antitumour 56 multiple myeloma MM 56 weekly subcutaneous injections 56 Pharmacokinetic studies 56 Adjuvant chemotherapy 56 noninfectious uveitis 56 androgen suppression 56 IMGN# 56 Vascugel 56 nanomolar 56 metastatic hormone refractory 56 vinca alkaloid 56 ToGA 56 AEGR 56 anti CD3 antibody 56 PARP inhibition 56 previously untreated follicular 56 Pazopanib 56 TriGrid ™ 56 DMARD 56 chemotherapeutics 56 DCVax R 56 chronic neuropathic pain 56 delayed CINV 56 intra arterial chemotherapy 56 dose corticosteroids